



British Association for
Community Child Health

Virtual Annual Scientific Meeting

5-6 October 2021

<u>Page</u>	
3	Welcome from the Academic Convenor
4	Programme for day one: Tuesday 5 October
5	Programme for day two: Wednesday 6 October
6-7	Speakers day one: Tuesday 5 October
8-9	Advertisements
10-12	Speakers for day two: Wednesday 6 October
13-16	Abstracts for oral presentations
17-18	List of posters (presented in random order)

Welcome to the Annual Scientific Meeting (ASM) of the British Association for Community Child Health (BACCH).

Last year, we did hope that this year's conference would not have to be held virtually. Unfortunately, and much to the annoyance of some of my colleagues at BACCH, that was not to be and here we are again.

Much effort has gone into organising the event and I hope that you will find this a highly valuable experience and a good investment of your time.

I am sure you would agree with me that all of us would like to come away from conferences and meetings with some practical tips to take home for use in our daily clinical practice. Towards this I have personally requested all our esteemed speakers to specifically add some slides on this too, to their research work that they would be presenting.

I would like to thank our Chair Dr Lisa Kauffmann and all members of our BACCH Executive Committee for their contributions in getting this event together. My Special Thanks as always to the extremely efficient BACCH office team - Isabelle Robinson and Prafula Bhadeshia.

Finally, it goes without saying that all these Academic Events are being made possible only due to your ongoing support to BACCH as BACCH members. If you have not yet joined, please consider doing so!

Have a great year till the next ASM. Thank you so much.

Alice S

Dr Alice Setti MBBS FRCPCH
BACCH Academic Convenor

#BACCH2021
#BACCHASM

All registered delegates will be emailed details of how to access the meeting by 4pm on Monday 4 October: please contact bacch@rcpch.ac.uk if you have not received this message.

Timings	Description
13.00-13.05	Virtual welcome from BACCH Deputy Academic Convenor Dr Jo Garstang
13.05-13.45*	<i>Life limiting illnesses in children – what do the data tell us?</i> (Professor Lorna Fraser , Professor of Epidemiology and Director of the Martin House Research Centre, University of York)
13.45-14.15**	<i>Abstracts</i> (see pages 13-14) 13.45-14.00 – Assessing variation in health assessment of unaccompanied asylum-seeking children (UASC): a cross-sectional survey across England (Dr Behrouz Nezafat Maldonado) 14.00-14.15 – Multiple Anticholinergic Use: multiple prescribers for multiple conditions with multiple adverse effects in children with severe neurodisability (Dr Jacqueline Emery)
14.15-14.55*	<i>Child safeguarding during the pandemic: what have we learnt from serious incident notifications?</i> (Dr Peter Sidebotham, Emeritus Professor of Child Health, Warwick Medical School)
14.55-16.00	Short video advertisement from Proveca
15.00-15.10	Break
15.10-15.40**	<i>Abstracts</i> (see pages 15-16) 15.10-15.25 – Prevalence of autism (ASD) in different racial groups in Europe, North America and Oceania, 2000-2020: a systematic review (Nathan Anorson) 15.25-15.40 – The experiences of mothers of children and young people with complex neurodisability during the COVID-19 pandemic: a qualitative study (Lily Hopkins)
15.40-16.05**	<i>Weigh to Go – improving growth measurement for disabled children</i> (Dr Catherine Tuffrey, Consultant Paediatrician, Solent NHS Trust / BACD Academic Convenor)
16.05-16.30**	<i>Continence matters for children and young people with neurodisability</i> (Professor Christopher Morris, Professor of Child Health Research, University of Exeter, Dr Anne Wright, Consultant Paediatrician, Evelina London Children's Hospital) & Davina Richardson, Children's Nurse, Bladder & Bowel UK)
16.30-16.35	End of day one round up from BACCH Deputy Academic Convenor

* includes 10 minutes for Q&A

** includes 5 minutes for Q&A

All registered delegates will be emailed details of how to access the meeting by 4pm on Monday 4 October: please contact bacch@rcpch.ac.uk if you have not received this message

Timings	Description
09.00-09.20	<i>AGM – BACCH Members only (separate meeting)</i>
09.45-09.50	Virtual welcome from BACCH Academic Convenor Dr Alice Setti
09.50-10.30*	Assessment and recommendations on orthotics needed by children with neurodisabilities (Eileen Morrow, Orthotist, Oxford University Hospitals / Pre-Doctoral Clinical Academic Fellow, Oxford University)
10.30-11.10*	Attachment disorders and how to differentiate Autism vs Attachment disorders (Dr Rebecca Stancer, Associate Professor, University of Plymouth & Professor Rudi Dallos, Emeritus Professor, University of Plymouth)
11.10-11.15	Short video advertisement from the Children's Trust
11.15-11.25	Break
11.25-12.00**	Audiovestibular paediatrics and CCH teams: Workforce, avoiding a crisis and the SPIN (Dr Tracey Davis, Consultant Community Paediatrician, British Association of Paediatricians in Audiology (BAPA))
12.00-12.25**	Recent developments in neurodevelopmental disorders (George Still Forum)
12.25-12.30	End of meeting round up (including awarding of prizes)

* includes 10 minutes for Q&A

** includes 5 minutes for Q&A

Participants can self-accredit for up to 5.5 CPD credits, in accordance with the current RCPCH CPD Guidelines

Lectures

Life limiting illnesses in children – what do the data tell us?

Professor Lorna Fraser (Professor of Epidemiology and Director of the Martin House Research Centre, University of York)

Synopsis

To provide an overview of what the data tells us about the population of children and young people with life limiting or life-threatening conditions, how we can use these data to improve access to services and the importance of clinician input into data collection.

Biography

Lorna Fraser is a Professor of Epidemiology and Director of the Martin House Research Centre at the University of York. The Martin House Research Centre is a multi-disciplinary centre for research on the care and support of children and young people with life limiting conditions or medical complexity, their families and the workforce that care for them. The Centre is holistic in its scope, recognising that the care and support needs of children and families span clinical/medical, social, psychological, parenting/caring, spiritual, financial and practical domains.

Lorna's background is in clinical paediatrics and main research areas are complex and life limiting conditions in childhood and how to utilise routinely collected health and administrative data to improve care for children.

Child safeguarding during the pandemic: what have we learnt from serious incident notifications?

Dr Peter Sidebotham (Emeritus Professor of Child Health, Warwick Medical School)

Synopsis

In this talk I will review findings from serious and fatal safeguarding incidents notified to the National Child Safeguarding Practice Review Panel during 2020, particularly focusing on those cases where the Covid-19 pandemic and subsequent lockdown may have had an impact. I will explore what these cases can teach us in relation to the impact on children and families and on how professionals worked together to safeguard children.

Biography

Peter Sidebotham is a retired paediatrician and emeritus professor of child health at the University of Warwick. As an academic paediatrician he specialised in child protection and was the designated doctor for child protection and for child death review in Warwickshire. Peter is a member of the National Child Safeguarding Practice Review Panel.

Peter's research includes studies on unexpected child deaths including sudden infant death syndrome, and work on child death review and child maltreatment. He has worked with Professor Marian Brandon from UEA on several national analyses of Serious Case Reviews. He is the author/editor of three books and several book chapters and has published extensively on child abuse and child death review.

Short Talks

Weigh to Go – improving growth measurement for disabled children

Dr Catherine Tuffrey (Consultant Paediatrician, Solent NHS Trust / BACD Academic Convenor)

Synopsis

The 2018 NCEPOD report Each and Every Need identified that a third to a half of all paediatric community, outpatient and inpatient facilities surveyed did not have appropriate scales to measure the weight of disabled children. Children were prescribed medication and taken for surgery without recent weight measurements, presenting a risk to provision of safe clinical care as well as missed opportunities for identifying nutritional and other growth problems. Recommendation 8 of the report states 'Patients with neurodisabling conditions should have their weight and nutritional status considered at every healthcare encounter and assessed and recorded based on clinical need' and in response to this, BACD have set up the 'Weigh to Go' initiative. This aims to encourage Trusts to ensure that they have appropriate equipment and processes to ensure this recommendation can be enacted. The talk will explain what clinicians need to do to become 'Weigh to Go' champions and encourage trust managers to engage, with the aim that all disabled children are treated equally to their able-bodied peers with respect to growth measurement and monitoring.

Biography

Catherine has been a consultant paediatrician in the community paediatric service, Solent NHS Trust in Portsmouth for 10 years. Prior to that, she completed a PhD at Newcastle University looking at measurement of social participation of disabled adolescents. She undertook Paediatric Neurodisability training in Wessex deanery. She is currently Academic Convenor for BACD.

Continence matters for children and young people with neurodisability

Professor Christopher Morris (Professor of Child Health Research, University of Exeter),

Dr Anne Wright (Consultant Paediatrician, Evelina London Children's Hospital) &

Davina Richardson (Children's Nurse, Bladder & Bowel UK)

Synopsis

We will summarise research commissioned by NIHR about improving continence of children and young people with neurodisability, then offer some clinical advice and practice tips.

Biographies

Chris leads PenCRU: the Peninsula Childhood Disability Research Unit, which undertakes a programme of applied health research aimed at identifying ways to improve the health and wellbeing of disabled children and their families. PenCRU involves families of disabled children as partners in all the activities of the unit through our Family Faculty. The vision for PenCRU is to work in partnership with families, clinicians and commissioners as the principal users of our research findings. For more information see www.pencru.org/

Anne is the lead consultant in charge of the Children's Bladder Clinic at Evelina London Children's Hospital, where she works closely with the nephrourology department. She is an expert in childhood bladder and bowel dysfunction including bedwetting, daytime wetting, giggle incontinence, constipation and soiling and neuropathic bladders. She is responsible for paediatric videourodynamic investigation within the service, which also offers uroflowmetry with electromyography (EMG), bladder scan, biofeedback and neuromodulation.

Davina is a children's specialist nurse, who has been working at Bladder & Bowel UK, a national charity under the umbrella of Disabled Living, for six years. She has experience nursing children in both the acute and community sectors of the NHS and worked for some years with children who have complex health needs including neurodisabilities. She set up and ran a community children's continence service in the NHS for over 10 years; this service included provision of support to children with difficulty toilet training. Davina is currently joint chair of the Paediatric Continence Forum and is on the Executive Committee of the Association for Continence Advice.

Sialanar®

(400mcg/ml glycopyrronium bromide
equivalent to 320mcg/ml glycopyrronium)

Sialanar® is the only anticholinergic licensed across Europe for the symptomatic treatment of severe sialorrhoea in children aged 3 years and older, with chronic neurological disorders.

Sialanar® as glycopyrronium should be considered for first line treatment

'There is increasing evidence that 1st line anticholinergic therapy should be glycopyrronium'¹

Where either hyoscine or glycopyrronium might be used, glycopyrronium should be the medication of first choice.²



Sialanar® has been designed for children.

A product designed for children in terms of taste, excipients and formulation:



Concentrated solution (2mg/5ml glycopyrronium bromide) therefore relatively small volume to swallow



Easy to titrate the dose with the oral dosing syringe



Raspberry flavouring increases the palatability for the patient



Licensed for use with PEG, GJ and nasogastric tubes

Prescribing Information UK

Sialanar® 320 micrograms /ml oral solution

Please refer to the full Summary of Product Characteristics (SmPC) before prescribing.

Presentation: Glycopyrronium oral solution in 250 ml or 60 ml bottle. 1 ml solution contains 400 micrograms glycopyrronium bromide, (equivalent to 320 micrograms of the active ingredient, glycopyrronium).

Indication: Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.

Dosage: Start with approximately 12.8 micrograms/kg body weight of glycopyrronium per dose, three times per day. Increase dose weekly until efficacy is balanced with side effects. Titrate to maximum individual dose of 64 mcg/kg body weight glycopyrronium or 6 ml three times a day, whichever is less. Monitor at least 3 monthly for changes in efficacy and/or tolerability and adjust dose if needed. Not for patients less than 3 or over 17 years old as Sialanar® is indicated for the paediatric population only. Reduce dose by 30%, in mild/moderate renal failure. Dose at least one hour before or two hours after meals or at consistent times with respect to food intake. Avoid high fat food. Flush nasogastric tubes with 10 ml water.

Contraindications: Hypersensitivity to active substance or excipients; pregnancy and breast-feeding; glaucoma; urinary retention; severe renal impairment/dialysis; history of intestinal obstruction, ulcerative colitis, paralytic ileus, pyloric stenosis; myasthenia gravis; concomitant treatment with potassium chloride solid oral dose or anticholinergic drugs.

Special warnings and precautions for use: Monitor anticholinergic effects. Carer should stop treatment and seek advice in the event of constipation, urinary retention, pneumonia, allergic reaction, pyrexia, very hot weather or changes in behaviour. For continuous or repeated intermittent treatment, consider benefits and risks on case-by-case basis. Not for mild to moderate sialorrhoea. Use with caution in cardiac disorders; gastro-oesophageal reflux disease; pre-existing constipation or diarrhoea; compromised blood brain barrier; in combination with: antispasmodics, topiramate, sedating antihistamines, neuroleptics/antipsychotics, skeletal muscle relaxants, tricyclic antidepressants and MAOIs, opioids or corticosteroids. Sialanar® contains 2.3 mg sodium benzoate (E211) in each ml. Patients require daily dental hygiene and regular dental checks. Thicker secretions may increase risk of respiratory infection and pneumonia. Moderate influence on ability to drive/use machines.

Fertility, pregnancy and lactation: Use effective contraception. Contraindicated in pregnancy and breast feeding.

Undesirable effects: Adverse reactions more common with higher doses and prolonged use. In placebo-controlled studies (≥15%) dry mouth, constipation, diarrhoea and vomiting, urinary retention, flushing and nasal congestion. In paediatric literature; very common: irritability, reduced bronchial secretions; common: upper respiratory tract infection, pneumonia, urinary tract infection, agitation, drowsiness, epistaxis, rash, pyrexia. The Summary of Product Characteristics should be consulted for a full list of side effects.

Shelf life: 2 years unopened. 2 months after first opening.

MA number:

Sialanar® 250 ml bottle – EU/1/16/1135/001
Sialanar® 60ml bottle – EU/1/16/1135/002

Legal Category:

POM

Basic NHS Price:

Sialanar® 250 ml bottle £320
Sialanar® 60ml bottle £76.80

Marketing Authorisation Holder (MAH):

Proveca Pharma Ltd, Marine House,
Clanwilliam Place, Dublin 2, Ireland
Further prescribing information can
be obtained from the MAH.

**Date of last revision of prescribing
information:** April 2019

References

- McDermott C. Developing the evidence base for the management of drooling. *Developmental Medicine & Child Neurology* 2020; 62: 266–273. doi: 10.1111/dmcn.14373
- Parr JR, Todhunter E, Pennington L, et al. Drooling Reduction Intervention randomized trial (DRi): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability. *Arch Dis Child* 2017; 0: 1–6. Doi:10.1136/archdischild-2017-313763

Date created: September 2021
UK-SIA-21-0076

Adverse events should be reported.
Reporting forms and information can be
found at: www.mhra.gov.uk/yellowcard

Adverse events should also be reported
to Proveca Limited. Phone: 0333 200
1866 E-mail: medinfo@proveca.com


Proveca
Medicines for Children



Placements available

Through our on-site specialist team, we provide **rehabilitation** and **specialist education** to **children and young people** aged 0-19 with **acquired brain injury, neurodisabilities and complex health needs.**

Located just south of London and set in 24-acres of beautiful woodland, our national specialist centre is the **UK's largest paediatric residential rehabilitation centre of its kind.**

We are able to offer **parent accommodation on-site** and **interpretation services** as required.

With our children and family services rated '**Outstanding**' by CQC and our school rated '**Good**' with '**excellent management and leadership**' by Ofsted, we are **currently accepting placements (including private patients)** across all areas of our service.



Our rehabilitation services aim to:

- maximise each child's potential
- restore lost skills where possible, develop alternative skills and provide compensatory aids as needed
- facilitate new learning beyond the end of the child's natural recovery period
- develop an understanding of the child's needs
- ensure the child's home environment is modified for the way they will function after their brain injury
- prevent secondary problems such as joint contractures developing.

For further information about our services, please contact our dedicated placements team on:

📞 01737 365 080 or
📧 placements@thechildrenstrust.org.uk



The Children's Trust is inspected and rated 'Outstanding' by CareQuality Commission and rated an 'Outstanding Provider' by Ofsted Care (for residential houses).
The Children's Trust School is rated a 'Good Provider' by Ofsted Education. The Children's Trust, Tadworth Court, Tadworth, Surrey KT20 5RU Registered charity number 288018. TCT_834 09/21

Lectures

Assessment and recommendations on orthotics needed by children with neurodisabilities

Eileen Morrow (Orthotist, Oxford University Hospitals / Pre-Doctoral Clinical Academic Fellow, Oxford University)

Synopsis

A brief overview of recent academic findings and clinical understanding of orthotics for children with neurodisabilities.

This presentation will explore the available evidence base of orthotic treatment for children with neurodisabilities and fill the gaps in evidence with clinical experience. A broad range of orthotic management will be discussed from toe walking to cerebral palsy, and helmets to ankle-foot orthoses. This presentation aims to provide you with an understanding of how orthotics can help your patients and what treatment limitations to consider.

Biography

Eileen Morrow has been an orthotist at Oxford University Hospitals since 2016 having graduated BSc (Hons) Prosthetics and Orthotics at the University of Strathclyde. She is the affiliated orthotist for the Oxford Gait Laboratory, using information from 3D instrumented gait analysis to advise on orthotic prescriptions. She also contributes to the associated research group, Research at Oxford on Analysis of Motion (ROAM). She is the prosthetics and orthotics representative on the committee of the Oxfordshire hub of the Council for Allied Health Professions Research (CAHPR).

In 2020 Eileen was awarded an NIHR/HEE Pre-Doctoral Clinical Academic Fellowship (PCAF) and started working at the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) at the University of Oxford.

Eileen has led a range of orthotics and orthopaedics related research. She has recently been involved in a project studying the forces used in Ponseti treatment for clubfoot in Ethiopia. Her current research is focused on interviewing allied health professionals to assess the key outcomes for children after elective lower limb orthopaedic surgery.

Attachment disorders and how to differentiate Autism vs Attachment disorders

Dr Rebecca Stancer (Associate Professor, University of Plymouth) & **Professor Rudi Dallos** (Emeritus Professor, University of Plymouth)

Synopsis

In this lecture we explore and question the nature of Autism Spectrum Disorder and common misunderstandings associated with Attachment Theory. We discuss overlap and intersection between autism and attachment difficulties including reference to the literature, clinical measures, diagnosis and family experience. We raise questions regarding current diagnostic practice and propose tentative solutions focusing on Formulation and early systemic intervention.

Biographies

Rebecca is an Associate Professor of Early Childhood and a lecturer at The University of Plymouth. She is also a Family Therapist and co-designer of the SAFE intervention programme for families of children with a diagnosis of autism. Rebecca's main research interest is Autism Spectrum Disorder in particular understanding family challenges associated with autism and developing interventions to address those challenges

Rudi Dallos is Emeritus professor of Clinical Psychology at the University of Plymouth. He is also a family therapist and has specialised in clinical work with families and children, presenting with eating disorders, self, harm, and recently autism. He has conducted research into family dynamics and attachment processes and over the last five years has collaborated with Rebecca Stancer on a major research trial for an evaluation of a manualised family therapy approach – SAFE for families with a child diagnosed with autism. He has published a range of journal articles and books including: Attachment Narrative Therapy, Introduction to Family Therapy, Formulation in Psychotherapy and Counselling and Don's Blame the Parents: Positive Intentions, Scripts and Change in Family Therapy.

Short talks

Audiovestibular paediatrics & CCH teams: Workforce, avoiding a crisis & the SPIN

Dr Tracey Davis (Consultant Community Paediatrician, British Association of Paediatricians in Audiology (BAPA))

Synopsis

This presentation will describe the workforce situation and health care needs of children with hearing impairment. It will cover:

- the central role of the paediatrician within the MDT
- data from three surveys BAPA have undertaken to highlight the pressing need to expand the workforce and consider the educational requirements of paediatricians
- the streams of work for an audiovestibular paediatric service and the other specialist colleagues within an MDT, or provided by networks of care
- an introduction to the paediatric audiovestibular medicine RCPCH SPIN (including the syllabus and training placement requirements as well as who can apply)
- brief review the application process and expectations of how this training might grow in future years

The aim is twofold. Firstly, that this presentation will be relevant to all community paediatricians. Secondly to expand the interest within CCH departments to ensure this special interest is maintained and/or developed within the teams. The long-term focus is for geographically available training and service delivery across all four nations of the UK. We will be starting with a handful of sites in the first year to enable close review while we pilot the syllabus. We would like to encourage expressions of interest.

Biography

Tracey trained in paediatrics at High Wycombe, Birmingham Children's Hospital, GOSH, Northampton and Oxford. She qualified as a Calman Trainee in Community Paediatrics in 1998 and has been working since then as a less than fulltime consultant community paediatrician at Northampton General Hospital (NGH). Initially most of her work was in neurodevelopmental paediatrics with a special interest in Downs syndrome. She completed the MSc in Community Paediatrics at Warwick University in 1996 with a dissertation in accident prevention.

She became the medical lead for audiovestibular paediatrics including team leading for the newborn hearing screening programme locally in 2003 and completed the UCL MSC in Audiovestibular Medicine in 2010.

She joined the BAPA executive Committee in 2017 as a supraregional rep for central, east and south-east England and the BAPA rep to the RCPCH in 2018. She has been working with colleagues at BAPA, the RCPCH and in Audiovestibular Medicine on the establishment of an RCPCH SPIN in Paediatric Audiovestibular Medicine.

Recent developments in neurodevelopmental disorders

Dr Neel Kamal (Convenor, George Still Forum) & **members of the GSF Executive**

Synopsis

Members of the GSF executive committee will present and share their expertise on various aspects of Attention Deficit Hyperactivity Disorder (ADHD). Topics will include current status of GSF organisation followed by a brief overview of ADHD, challenges relating to diagnosis, including preschool ADHD, associated comorbid neurodevelopmental disorders and the management of ADHD in the digital age.

Biographies

Individual biographies to follow.

The aims and objectives of the George Still Forum are to exchange ideas, to increase professional awareness, to liaise with other professional groups, to influence public policy decisions where appropriate, to share information in relation to current issues in providing services to individuals and their families and to improve care and increased awareness of ADHD in children and adolescents.

Assessing variation in health assessment of unaccompanied asylum-seeking children (UASC): a cross-sectional survey across England

Presenter: Dr Behrouz Nezafat Maldonado (Academic Clinical Fellow in Paediatrics / Paediatric Speciality Trainee, Imperial College London)

Authors: Behrouz Nezafat Maldonado, Alice Armitage, Bhanu Williams

Introduction:	According to statutory guidance, all UASC have an initial health assessment (IHA) within 28 working days of arrival. There is a lack of standardisation around how these assessments are undertaken including type of doctor, training in this area, translator facilities, MDT involvement, screening investigations and thresholds for onward referral.
Aims:	We aimed to survey current practice of IHAs for UASC across England; With a view to assessing variation in care (both positive and negative) and identify targets for intervention and standardisation. Secondary aims were to inform policy recommendations around UASC management and to inform future research direction. No ethical approval required.
Methods:	Between March and June 2021, an online survey was distributed to healthcare professionals across England working with UASC via professional networks and special interest groups. The survey consisted of 5 key themes: (1) Demographics, (2) Local health system, (3) Initial Health Assessment procedures, (4) Training and (5) Current Situation.
Results:	86 respondents. IHA: 80% with translator, 7% had CAMHS present. Training received: 46% in UASC IHA, 33% in UASC mental health. IHA duration: 43% 30-60 min, 57% >60 min. Infectious diseases screening: 65% performed universal screening for all, 26% risk-assessed, 2% symptom-based, 7% none. IHA report: 14% comment on age, 76% share report with UASC.
Conclusions:	Our findings show significant variation in practice around UASC IHAs across England, particularly around CAMHS input, time allocated, translation facilities and ID screening. Results suggest a need for increased education and training on UASC for professionals and need for standardisation in IHA delivery including MDT involvement and screening.

Multiple Anticholinergic Use: multiple prescribers for multiple conditions with multiple adverse effects in children with severe neurodisability

Presenter: Dr Jacqueline Emery (Specialty doctor in community paediatrics and neurodisability, Chailey Clinical Services)

Authors: Jacqueline Emery, Patricia Freeman, Vivienne Campbell

Introduction:	The involvement of a clinical pharmacist with the medical team offered the opportunity to critically survey prescribing practices in a large school and residential home for CYP aged 5 to 25 years who have severe neurodisability. This project examined outpatient prescribing of anticholinergic medications
Aims:	To survey types and patterns of anticholinergic medications prescribed regarding indications, presence of adverse effects and how these were detected in a nonverbal population and if consideration of polypharmacy was documented.
Methods:	Search of CYP electronic medication charts for prescriptions of anticholinergic medications (glycopyrronium , hyoscine, trihexiphenidyl, ipratropium , oxybutynin, tolterodine), as well as medication which may be used to counter side effects of anticholinergic medications for instance laxatives and saline nebulizers.
Results:	<p>A total of 106 CYP were surveyed, 64 were prescribed anticholinergics. 22 were prescribed two or more.</p> <p>Of those on multiple anticholinergics 6/22 were also receiving nebulized saline for thick secretions, 19/22 were on treatment for constipation. None had clear documentation of potential side effects, one highlighted polypharmacy as a 'problem'.</p>
Conclusions:	Multiple anticholinergic use is common, and sometimes helpful, in CYP with neurodisability, albeit with predictable adverse effects. We were surprised by the information revealed in this project and use this project to aid prescriber : family discussions.

Prevalence of autism (ASD) in different racial groups in Europe, North America and Oceania, 2000-2020: a systematic review**Presenter:** Nathan Anorson (Medical Student, Brighton and Sussex Medical School)**Authors:** Nathan Anorson, Ian Male, William Farr, Anjum Memon

Introduction:	The prevalence of autism is a subject that has been widely researched and reported, with increases in prevalence estimates since 1966. Global prevalence is approximated to be 1-2%. Despite the abundance of research, there is limited research on prevalence of autism according to different ethnic and racial groups.
Aims:	To determine overall prevalence of autism and prevalence of autism according to ethnicity/race in Europe, North America and Oceania from 2000 to 2020.
Methods:	The databases MEDLINE and PSYCINFO were searched for ASD studies estimating the prevalence of ASD in various regions across Europe, North America and Oceania published between 2000 and 2020 (including data from 1993-2019). Prevalence per 10,000 population was extracted and prevalence according to race/ethnicity was calculated.
Results:	75 studies were included, with 18 studies reporting on autism prevalence by race. These studies revealed differences in autism prevalence between racial groups. For White children, the median prevalence was 36.0 per 10,000 population. For Black and Asian children, the median prevalence was 23.0 per 10,000 population. For Hispanic children, the median prevalence was 18.0 per 10,000 population.
Conclusions:	There is variation in prevalence of autism between different racial groups. Several factors may contribute to this, including negative attitudes towards autism and challenges in engaging with services among ethnic minority groups. Further research is needed to determine reasons for the differences in prevalence in order to inform services.

The experiences of mothers of children and young people with complex neurodisability during the COVID-19 pandemic: a qualitative study

Presenter: Lily Hopkins (Master's Student, University College London)

Authors: Lily Hopkins, Io Vassiliadou, Emma Wilson, Michelle Heys

Introduction:	Disruption to healthcare or educational services during the COVID-19 pandemic may have disproportionately impacted caregivers of children with complex neurodisability (or SEND), exacerbating existing health inequalities for this group. Services must understand the experiences of caregivers during the pandemic to effectively address their needs.
Aims:	We aim to (i) explore the experiences of parents/caregivers of children with complex neurodisability during the COVID-19 pandemic; (ii) examine the needs for this group in terms of mitigating the direct and indirect impacts of COVID-19 and thus (iii) address significant research and public health gaps in understanding needs of this population.
Methods:	Semi-structured interviews were conducted with 7 parents of children with diagnoses of SEND or complex neurodisability living in an inner-city borough of London. Barriers to recruitment were experienced mainly related to participant time and availability. A combination of deductive and inductive thematic analysis was conducted.
Results:	Eight main themes arose: service use and support; coping; society, media and government; relationships and social support; perceptions and feelings; impact on health and wellbeing; impact on daily life and routine and changes throughout time or lockdowns. Despite the small sample, results are similar to larger studies in comparable London boroughs.
Conclusions:	Parents highlighted the importance of access to in person schooling and/or tailored resources during the pandemic. The adverse impact of the lockdowns on parent's mental health and weight was also described. Parents cited a need for more face-to-face input from services. These data support a renewed focus on equity and services for this population.

- **Posters titles are presented in random order**
- **PDF of all posters available as a separate document [from the event web page](#)**
- **The prize for best poster will be awarded at the end of day two of the conference**

Name(s) of author(s)	Full title of abstract
Dr Ayaz Vantra	<i>Quality Improvement Project: Use of templates to improve quality of health recommendations advice for Initial Health Assessments for Looked After Children.</i>
Dr Robert Alexander Walsh (co-author); Dr Vivienne Campbell (co-author)	<i>Reducing Radiation Burden in the Management of Spinal Deformity</i>
Thomas Slater, Divya Pore	<i>Referral and Diagnosis of Autism: Experiences of Parents during the COVID-19 Pandemic</i>
Collingwood L, Ball E, Lloyd S, Murugesan D, Lant A, Harris S, Davies H, Robb P, Bhamkar R, Payne E	<i>What Effect has COVID-19 had on Child Protection Medicals?</i>
Dr Debbie Levene and Dr Nicole Horwitz	<i>Retrospective quality improvement project in feedback provision following an autism diagnostic assessment and diagnosis of Autism Spectrum Condition (ASC)</i>
Hannah Dumelow, Annaliese Buckland	<i>Ear Bruising in Children Referred for a Child Protection Medical</i>
Rubab Abdi, Molly Townson (joint first authors), Sveta Alladi	<i>The complexity of safeguarding in an east London borough: social, economic and cultural factors</i>
Cecelia Marsh, Layla Buckham, Sarah Mills	<i>Obesity in Looked After Children in Sunderland</i>
EJ Radford, A Burman, H Dolling, DH Rowitch, FL Raymond, HV Firth, A Sansome	<i>The Community Child Health care of children with genetic diagnoses</i>
Dr. Nkiru Asiegbunam; Colette Laws-Chapman, Dr. Stacy John-Legere	<i>Report on a virtual pilot of Child Protection Simulation Training in the Community during the Covid-19 pandemic</i>

Name(s) of author(s)	Full title of abstract
Dr Saba Hussain and Dr Saraswati Hosdurga	<i>Differential Attainment in Career Progression of Doctors in the UK-Literature review</i>
Dr Alexandra Ho, Dr Nikhita Joglekar, Dr Jeyoung Lee, Dr Alison Sansome	<i>An assessment of the ability of primary care to monitor vital signs in a paediatric population</i>
Dr Catherine Grilli	<i>Please Write to Me: Should we be addressing outpatient letters directly to patients and their families in community child health?</i>
Nkiru Asiegbunam, Rachel Coogan, Gul Heptinstal, Brenda Nakamya, Annelie Visser, Deborah Paton.	<i>Joint Health and Social Care Quality Improvement Project - Report on a 6 week pilot Child Protection Strategy Discussions</i>
Dr. Nkiru Asiegbunam; Dr. Stacy John-Legere	<i>Clinician's experience of conducting Child Protection Medical Assessments during the Covid-19 pandemic.</i>
Dr. Nkiru Asiegbunam; Helen Stewart Named Nurse Safeguarding Children (Retired)	<i>Safeguarding Advice: what works for frontline practitioners?</i>
Thushara Latha Perumal, Samira Nur, Madhumita Mukherjee	<i>Cooped up & Staring at Screens: A Paediatric Survey Studying Compliance to Attention Deficit Hyperactivity Disorder (ADHD) Medication and the Effect of the COVID-19 Lockdowns on Symptom Control</i>
Dr Saba Hussain, Dr Emma Bradley	<i>The impact of acute out of hours (OOH) rota on the learning opportunities of Community Child Health (CCH) grid trainees.</i>
Dr Eleanor Boddy, Dr Rachel Bower, Dr Nicola Herberholz, Dr Gillian Mitchell, Dr Kim Pierson, Dr Toks Sanwo	<i>ARFID: the tip of an iceberg? Understanding the need for and improving services offered for Community Paediatric patients with restrictive eating patterns</i>
Luke Scott, 15, Ollie Rawlinson-John, 16, James McCann, 17, and Marcus Ashall-Payne, 16	<i>Project Clear Minds: teen boys help other teens find mental health support</i>